Affiliation:
1. Universidade Lusófona
2. Centro Hospitalar Universitário do Algarve Unidade de Portimão
3. Estrada Costa Cruz Quebrada
4. Universidade do Porto
Abstract
Abstract
Introduction. Hormonal therapy has adverse effects that hinder breast cancer survivors' functional performance and quality of life. Physical activity (PA) can counteract these adverse effects, and home-based exercise interventions might be a potential solution to foster PA adoption in this population. This study aimed to investigate home-based exercise intervention effects on functional performance, quality of life and PA of breast cancer survivors’ undergoing hormonal therapy. Adherence to the intervention and adverse events were also reported.
Method. This study was a 12-week randomised controlled trial comprising a home-based exercise intervention supported by an exercise booklet including six exercise groups and a weekly online exercise group session. Eighteen women were recruited from Hospital Universitário do Barlavento Algarvio.
Results. Significant time-by-group effects in functional performance (sit-to-stand (p=.033), arm curl (p=.011), and timed up-and-go (.009) tests), quality of life (insomnia (p=.007) and breast symptoms (p=.035)), and PA (vigorous PA (p=.033), walking (p=.005), and total PA (p=.034)), favouring the intervention group were found. Attendance to the supervised component of the program was high (80%).
Conclusion. This home-based exercise intervention was well tolerated and accepted by participants and led to significant improvements in functional performance and PA levels. These findings further support the effectiveness of this type of intervention, which is a more affordable and viable strategy to raise PA levels and enhance functional performance in breast cancer survivors. Exercise professionals may use these programs to promote active lifestyles while reducing barriers to practice.
Publisher
Research Square Platform LLC
Reference48 articles.
1. C. Fitzmaurice e Global Burden of Disease Cancer Collaboration, «Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: A systematic analysis for the Global Burden of Disease study.», J. Clin. Oncol., vol. 36, n.o 15_suppl, pp. 1568–1568, mai. 2018, doi: 10.1200/JCO.2018.36.15_suppl.1568.
2. Giaquinto AN et al. «Breast Cancer Statistics, 2022», CA. Cancer J. Clin., vol. 72, n.o 6, pp. 524–541, nov. 2022, doi: 10.3322/caac.21754.
3. Burstein HJ et al. «Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update», J. Clin. Oncol., vol. 37, n.o 5, pp. 423–438, 2018.
4. Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline»;Tamirisa N;Ann Surg Oncol
5. Visvanathan K et al. «Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update», J. Clin. Oncol., vol. 37, n.o 33, pp. 3152–3165, nov. 2019, doi: 10.1200/JCO.19.01472.